GlassScriptPhysician profile
Richard W Lowry
NPI 1699712703
$6,889.99
in general payments reported to CMS, 2019-2025
28 companies · $758 in 2025
The $758 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $725 · 2020: $813 · 2021: $1,198 · 2022: $1,167 · 2023: $1,114 · 2024: $1,115 · 2025: $758.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,988.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,987.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,415.41 | 2019-2025 | Aveir, Assurity, Gallant |
| Novartis Pharmaceuticals Corporation | $1,188.90 | 2019-2025 | |
| Amgen INC. | $763.34 | 2019-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $761.56 | 2019-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $399.29 | 2021-2025 | Verquvo, Belsomra |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $377.58 | 2019-2025 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $264.96 | 2020-2025 | Jardiance |
| Medtronic, INC. | $258.69 | 2021-2024 | Symplicity G3 |
| Pfizer INC. | $239.15 | 2020-2025 | |
| Astrazeneca Pharmaceuticals LP | $176.24 | 2020-2025 | Farxiga, Lokelma |
| Cvrx, INC. | $127.04 | 2022-2025 | Barostim Neo System |
| Novo Nordisk INC | $126.63 | 2021-2024 | Rybelsus, Ozempic |
| Cardiovascular Systems INC. | $117.47 | 2022 | |
| Gilead Sciences, INC. | $111.86 | 2019 | |
| Abiomed | $92.61 | 2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Atricure, INC. | $68.76 | 2022 | |
| Sanofi-Aventis U.S. LLC | $67.62 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $56.02 | 2019-2022 | |
| Irhythm Technologies, INC. | $53.60 | 2019-2024 | Zio Xt Patch, Zio Monitor |
| Impulse Dynamics (USA) INC. | $40.07 | 2021-2023 | Optimizer |
| Kiniksa Pharmaceuticals International, Plc | $38.61 | 2024 | Arcalyst |
| Siemens Medical Solutions USA, INC. | $27.70 | 2023-2024 | Artis Icono Biplane, Artis Icono Floor |
| Vifor Pharma, INC. | $27.54 | 2021 | |
| Alnylam Pharmaceuticals INC. | $21.67 | 2021 | |
| Acist Medical Systems, INC. | $21.51 | 2019 | |
| Astellas Pharma US INC | $16.05 | 2020 | |
| Philips North America LLC | $15.85 | 2023 | |
| Lundbeck LLC | $14.26 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Lowry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.